1. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model
   Guanwei Li et al, 2016, Biochemical Pharmacology CrossRef
2. The effect of mechanical force in genitourinary malignancies
   Kai Huang et al, 2022, Expert Review of Anticancer Therapy CrossRef
3. Can bladder fibrosis in congenital urinary tract obstruction be reversed?
   Yu Tao Lu et al, 2017, Journal of Pediatric Urology CrossRef
4. Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF-β1/Smad/CTGF signaling pathway
   Yan-Wu Sun et al, 2018, European Journal of Pharmacology CrossRef
5. The effect of an antifibrotic agent, pirfenidone, on penile erectile function in an experimental rat model of ischemic priapism
   Onder Cinar et al, 2020, International Journal of Impotence Research CrossRef
6. Urinary bladder organ hypertrophy is partially regulated by Akt1-mediated protein synthesis pathway
   Li-Ya Qiao et al, 2018, Life Sciences CrossRef
7. Antifibrosis treatment by inhibition of VEGF, FGF, and PDGF receptors improves bladder wall remodeling and detrusor overactivity in association with modulation of C‐fiber afferent activity in mice with spinal cord injury
   Joonbeom Kwon et al, 2021, Neurourology and Urodynamics CrossRef
8. Pirfenidone suppresses TGF‑β1‑induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K/AKT signaling pathway
   Yanwu Sun et al, 2018, Molecular Medicine Reports CrossRef
9. Expression of NGF, MCP-1, uroplakin III, and NOS in bladder urothelium after partial urethral obstruction in rats
   Hayrettin Ozturk et al, 2020, Journal of Pediatric Urology CrossRef